Uric acid‐lowering effects of sodium‐glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta‐analysis
Authors' conclusion
SGLT2 inhibitors reduced UA levels and cardiovascular events independently of heart failure status.
Study context
- Population
- Patients in large-scale SGLT2i trials (54% with HF); MEDLINE and EMBASE searched to 30 June 2023
- Participants
- 31,535 patients5 trials
- Comparison
- SGLT2i vs control: effect per 1 mg/dl uric acid (UA) reduction
- Outcome
- Cardiovascular events and mortality per 1 mg/dl reduction in UA
Methodological detailsrandom-effects meta-analysis, meta-regression of 1 mg/dl UA reduction
- Random-effects meta-analysis
- Meta-regression of 1 mg/dl UA reduction
Pooled result
As reported in the abstract
Per 1 mg/dl UA reduction · median follow-up 2.2 years
Composite of CV death and hospitalization for HF, HR
0.64
95% CI 0.46–0.88
Hospitalization for HF, HR
0.68
95% CI 0.62–0.74
Further pooled results
Mean reduction in UA with SGLT2i · median follow-up 2.2 years
- Mean UA reduction, mg/dl
- −0.79 (95% CI −1.03 to −0.54)
Original publication
Uric acid‐lowering effects of sodium‐glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 5 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →